pLenti-DHB-mVenus-p2a-mCherry-CDK4KTR Citations (7)
Originally described in: Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation.Yang HW, Cappell SD, Jaimovich A, Liu C, Chung M, Daigh LH, Pack LR, Fan Y, Regot S, Covert M, Meyer T Elife. 2020 Apr 7;9. pii: 44571. doi: 10.7554/eLife.44571. PubMed Journal
Articles Citing pLenti-DHB-mVenus-p2a-mCherry-CDK4KTR
| Articles |
|---|
| Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Kim S, Carvajal R, Kim M, Yang HW. Cell Rep. 2023 Jun 27;42(6):112570. doi: 10.1016/j.celrep.2023.112570. Epub 2023 May 29. PubMed |
Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer.
Kim S, Armand J, Safonov A, Zhang M, Soni RK, Schwartz G, McGuinness JE, Hibshoosh H, Razavi P, Kim M, Chandarlapaty S, Yang HW.
Cell Rep. 2023 Nov 28;42(11):113198. doi: 10.1016/j.celrep.2023.113198. Epub 2023 Oct 21.
PubMed
Associated Plasmids |
| Sustained ERK signaling promotes G2 cell cycle exit and primes cells for whole-genome duplication. Guerrero Zuniga A, Aikin TJ, McKenney C, Lendner Y, Phung A, Hook PW, Meltzer A, Timp W, Regot S. Dev Cell. 2024 Jul 8;59(13):1724-1736.e4. doi: 10.1016/j.devcel.2024.03.032. Epub 2024 Apr 18. PubMed |
| Oncogenic YAP sensitizes cells to CHK1 inhibition via CDK4/6 driven G1 acceleration. Gertzmann D, Presek C, Mattes AL, Sanger M, Zoller M, Schulein-Volk C, Ade CP, Eilers M, Gaubatz S. EMBO Rep. 2025 Aug;26(16):4017-4039. doi: 10.1038/s44319-025-00514-5. Epub 2025 Jul 4. PubMed |
| E2F activity determines mitosis versus whole-genome duplication in G2-arrested cells. Kim K, Armand J, Kim S, Yang HW. Nat Commun. 2025 Jul 21;16(1):6677. doi: 10.1038/s41467-025-62061-w. PubMed |
| Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models. Kim S, Son E, Park HR, Kim M, Yang HW. J Clin Invest. 2025 Aug 12;135(20):e188839. doi: 10.1172/JCI188839. eCollection 2025 Oct 15. PubMed |
| Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. Armand J, Kim S, Kim K, Son E, Kim M, Kalinsky K, Yang HW. Elife. 2025 Dec 29;14:RP104545. doi: 10.7554/eLife.104545. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.